IP Library Granted Patent US 7,348,346
Granted Patent B2
US 7,348,346 · App. 11/075,319 · Granted Mar 25, 2008

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,348,346
App. No.
11/075,319
Granted
Mar 25, 2008
Kind
B2
Abstract

The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

Claims (75)

1. A compound of formula (IV),

or therapeutically suitable salt, ester or prodrug, thereof, wherein

is a member selected from the group consisting of a single and double bond;

D is a bond or is a member selected from the group consisting of —C(O)—, —C(O)—N(R b )—, —N(R b )—, —N(R b )—C(O)—, —N(R b )—S(O) 2 —, —O—, and —S(O) 2 —N(R b )—;

L is a member selected from the group consisting of a bond, —(CH 2 ) m —CR d R e —(CH 2 ) n —, aryl, cycloalkyl, and heterocycle;

m and n are each independently 0, 1, 2, 3 or 4;

R 1 is a member selected from the group consisting of aryl, alkyl, arylalkyl, cycloalkyl and heterocycle;

R a and R b are each independently members selected from the group consisting of hydrogen, alkyl, arylalkyl and heterocyclealkyl and hydroxyalkyl;

R d and R e are each independently members selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, halo, haloalkyl, heterocycle, heterocyclealkyl, hydroxy and hydroxyalkyl, and R d and R e taken together with the atom to which they are attached form cycloalkyl; and

X is a member selected from the group consisting of —CH 2 —, —CHF—, —CF 2 —, —O—, —S— and —CH 2 O—.

2. The compound according to claim 1 , that is a member selected from the group consisting of

(3S, 5S)-Pentanedioic acid phenylamide-5-(thiazolidine-3-(carbonyl)-pyrrolidin-3-yl)methyl)-amide;

(3S, 5S)-2-(4-methanesulfonyl-phenyl)-N-(5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl)-acetamide;

(3S, 5S)-N-({[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-carbamoyl}-methyl)-benzamide;

(3S, 5S)-2-(4-Hydroxy-trans-cyclohexylamino)-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-acetamide;

(3S, 5S)-2-(3-Methoxy-phenoxy)-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-acetamide;

(3S, 5S)-N-5-(thiazolidine-3-carbonyl)-pyrrolidine-3-ylmethyl)-2-(toluene-4-sulfonylamino)acetamide;

(3S, 5S)-4-(4-Methoxy-phenyl)-4-oxo-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-butyramide;

(3S, 5S)-1-(4-Cyano-phenyl)-3-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-urea;

(3S, 5S)-1-Cyclopentyl-3-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-urea;

(3S, 5S)-N-[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-isophthalamic acid methyl ester;

(3S, 5S)-N-Methyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-Bromo-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-2,3-Dimethyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-N-[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-isophthalamic acid;

(3S, 5S)-3-Methanesulfonyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-4-Hydroxy-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-2,2-Difluoro-benzo[1,3]dioxole-5-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-N-[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-3-trifluoromethoxy-benzamide;

(3S, 5S)-N-[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-3-[1,2,4]triazol-1-ylmethyl-benzamide;

(3S, 5S)-3-Chloro-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-(1H-Tetrazol-5-yl)-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-2,3-Dihydro-benzofuran-5-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-3-Methanesulfonylaminocarbonyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-4-Phenoxymethyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-Imidazol-1-ylmethyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-N-[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-Acetyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-Benzo[1,3]dioxole-5-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-4-Methanesulfonyl-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-Dimethylamino-N-[5-(pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-4-Phenoxy-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-Amino-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-4-Hydroxy-N-[5-(pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-Hydroxy-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-N-[5-(Pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-isophthalamic acid;

(3S, 5S)-3-Dimethylamino-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-3-Methoxy-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-N-[5-(Pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-isophthalamic acid methyl ester;

(3S, 5S)-Quinoxaline-6-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-2-Amino-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide;

(3S, 5S)-Benzo[1,3]dioxole-5-carboxylic acid [5-(pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-2,3-Dihydro-benzofuran-5-carboxylic acid [5-(pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-Pyridine-2-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-1-Methyl-1H-pyrrole-2-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-1-Phenyl-cyclopropanecarboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-Thiazole-4-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-Thiophene-3-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-6-Chloro-N-[5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-nicotinamide;

(3S, 5S)-1H-Indole-3-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-3-Methyl-thiophene-2-carboxylic acid [5-(pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-Furan-2-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-Pyrazine-2-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-3-Methyl-thiophene-2-carboxylic acid [5-(thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-Thiazole-4-carboxylic acid [5-(pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-Cyclohexanecarboxylic acid [5-(pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-carbamic acid phenyl ester;

(3S, 5S)-[5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-carbamic acid 2-chloro-benzyl ester;

(3S, 5S)-Benzo[1,3]dioxole-5-carboxylic acid [5-(3,3-difluoro-pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-amide;

(3S, 5S)-N-[5-(3,3-Difluoro-pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-3-methoxy-benzamide;

(3S, 5S)-N-[5-(3,3-Difluoro-pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-isophthalamic acid methyl ester;

(3S, 5S)-N-[5-(3,3-Difluoro-pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-isophthalamic acid; and

(3S, 3′R, 5S,)-N-[5-(3-Fluoro-pyrrolidine-1-carbonyl)-pyrrolidin-3-ylmethyl]-isophthalamic acid; and

(3S, 5S)-3-Methanesulfonyl-N-[5-(morpholine-4-carbonyl)-pyrrolidin-3-ylmethyl]-benzamide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030182/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2005
From: AKRITOPOULOU-ZANZE, IRINI; DARCZAK, DARIA; DINGES, JURGEN; HOFF, ETHAN D.; PATEL, JYOTI R.; DJURIC, STEVAN W.; KOPECKA, HANA A.; PEI, ZHONGHUA; SHUAI, QI; SHAM, HING L.; SARRIS, KATHY; WIEDEMAN, PAUL E.
To: ABBOTT LABORATORIES
Reel/Frame 016292/0660 →